Serum PON3 concentrations have been reported to increase in patients with CHB or cirrhosis and showed significant direct correlations with the degree of periportal abnormalities including fibrosis and with serum FAS (a marker of antiapoptosis) concentrations [48]; however, serum gelsolin level has been reported to reduce significantly in patients with acute liver failure (47%), myocardial infarction (69%), sepsis (51%), and myonecrosis (66%) [49]. This evidence concerns the gene PON3 and acute liver failure.